The "Efficacy Approach": Infusion Therapies in the Treatment of Relapsing-Remitting Multiple Sclerosis

William Heuser1*, Cheng-Hsiao Tai2, Michael Harrington3 and Christopher Giacalone1

1Division of Clinical Pharmacy, Northwell Health Long Island Jewish Medical Center, New Hyde Park, NY, USA
2Division of Clinical Pharmacy, Northwell Health Lenox Hill, New York, USA
3Department of Pharmacy, Stamford Hospital, Stamford, CT, USA

*Corresponding author: William Heuser, Division of Clinical Pharmacy, Northwell Health Long Island Jewish Medical Center, New Hyde Park, NY, USA, E-mail: Heuserw@stjohns.edu

Rec date: October 04, 2016, Acc date: October 24, 2016, Pub date: October 26, 2016

Abstract

Multiple sclerosis (MS) is among the most common causes of neurological disability in young adults. As an immune-mediated inflammatory demyelinating disease of the central nervous system (CNS), treatment is aimed at decreasing the rate of relapse and slowing the accumulation of brain lesions on MRI readings. A number of immune-modulatory treatments are currently available that effectively reduce the relapse rate, however they are not curative. An algorithm presently exists, but the choice of specific agent should be individualized according to disease activity, patient values, and preferences. This review will focus on the use of infusion therapies that have been studied for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab and Alemtuzumab have been studied extensively in phase III clinical trials and are considered to be highly effective for the treatment of RRMS. In comparison, mitoxantrone, which is an immunomodulatory agent used in relapsing-remitting and progressive forms of MS, has limitations due to the risk for cardiac toxicity and limited evidence of clinical benefit. Infusion therapies with Natalizumab and Alemtuzumab have truly changed the treatment of RRMS and their significant advantages and benefits should not be discounted.

Keywords: Multiple sclerosis; Treatment; Infusion therapies; Relapsing-remitting multiple sclerosis

Introduction

Multiple sclerosis (MS) is a chronic autoimmune neurological disease of the CNS affecting the myelin and is considered to be the most common immune-mediated inflammatory demyelinating disease of the CNS [1]. MS attacks the myelinated axons in the CNS resulting in the destruction and dysfunction of the myelin and axons. As MS is characterized as an autoimmune disease, the pathology revolves around the infiltration of immune cells across the blood brain barrier (BBB) promoting inflammation, demyelination, gliosis, and neuroaxonal degeneration, resulting in the development of lesions in the CNS and the disruption of neuronal signaling [2]. Consequently, many of these individuals who have MS will inadvertently experience progressive neurological deficits that are reversible at first but progressively develop to become irreversible. Individuals with MS who are symptomatic will often experience sensory disturbances such as paresthesias, dysesthesias, diplopia, ataxia, vertigo, and bladder irregularities. Furthermore, these sensory disturbances may evolve into chronic neuropathic pain, trigeminal neuralgia, optic neuritis and complete or partial loss of vision [1]. MS is a chronic disease that disables and debilitates an individual resulting in a decrease quality of life. Therefore, it is necessary to manage patients who are diagnosed with this condition. Although there is no cure-all treatment available, there are disease modifying drugs that provide symptomatic relief, reduce duration of acute exacerbations, and prevent recurrences. More importantly these medications can reduce the severity and progression of the relapsing forms of MS.

Natalizumab

Natalizumab (Tysabri®), a recombinant, humanized antibody, is a new disease modifying therapy for the treatment of RRMS. Natalizumab is a selective adhesion molecule inhibitor that binds to α4β1-integrin (a surface adhesion molecule found on leukocytes) and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions [3]. There are two randomized phase III trials of natalizumab in patients with relapsing MS, which assessed the drugs clinical efficacy in the management of MS. The AFFIRM study concluded that natalizumab significant improved quality of life by reducing risk of sustained progression of disability and rate of relapses in comparison to placebo [4]. Furthermore, the SENTINEL study compared the addition of natalizumab to standard regimen of intramuscular interferon β-1a vs. intramuscular interferon β-1a (IFNβ-1a) alone. The study concluded that the addition of natalizumab was significantly more efficacious than IFNβ-1a alone [5]. In all phase II trials, natalizumab was well tolerated and had similar side effect profile to that of placebo. In the AFFIRM trial, the incidence rates of adverse drug events were not significantly different between natalizumab and placebo except for fatigue (27% vs. 21%, respectively; p<0.05) and allergic reactions (9% vs. 4%; p<0.05). On the other hand, in SENTINEL, combination therapy with natalizumab showed higher incidence of anxiety (12% vs. 8% in patients receiving IFNβ-1a alone), pharyngitis (7% vs 4%), sinus congestion (6% vs. 3%), and peripheral edema (5% vs. 1% (all p<0.05) [3]. Overall, natalizumab’s role in the management of MS appears to be one of great value as there are advantages including a tolerable side effect profile, unique mechanism
Alemtuzumab

Alemtuzumab (Lemtrada®) is a humanized monoclonal antibody used to treat adults with relapsing forms of multiple sclerosis. Alemtuzumab should be reserved for patients with an inadequate response to at least two drugs indicated for the treatment of multiple sclerosis [6]. Alemtuzumab was originally designed for the treatment of leukemias [7], and eventually a role was found in the treatment of multiple sclerosis. Alemtuzumab works by targeting CD52, an antigen with unknown function, which is expressed on T and B lymphocytes [8]. The employment of Alemtuzumab depletes CD52-bearing B and T cells through antibody-dependent cellular cytolysis and complement-mediated lysis [9]. It is important to note that although Alemtuzumab rapidly depletes T-cells, B-cells, natural killer (NK) cells and monocytes, the repopulation of T and B cells occurs only after the therapy is stopped. The efficacy and safety of alemtuzumab was evaluated in two phase 3 studies, the comparison of Alemtuzumab and Rebif Efficacy in MS (CARE-MS I) and II. All primary outcomes for the treatment of relapsing-remitting MS were reported versus SC IFNβ-1a, not placebo. In CARE-MS I, alemtuzumab reduced the absolute risk reduction by 55% (p<0.0001) compared with SC IFNβ-1a. There was a 30% reduction in six-month sustained accumulation of disability, however, statistical significance was not achieved (alemtuzumab, 8% vs SC IFNβ-1a, 11%; p=0.22). Side effects seen in CARE-MS I were infections of mild or moderate severity (90% in the alemtuzumab group vs. 45% in the IFNβ-1a group) and thyroid-associated adverse events (by 24 months, 18% in the alemtuzumab group vs. 6% in the IFNβ-1a group) [10]. In CARE-MS II, alemtuzumab reduced the absolute risk reduction by 49% (p<0.0001) and six-month sustained accumulation of disability by 42% (alemtuzumab, 13% vs SC IFNβ-1a, 21%; p=0.0084) over two years. Side effects seen in CARE MS II were nearly identical to side effects seen in CARE MS I. Infections (77% in the alemtuzumab group vs. 66% in the IFNβ-1a group) and thyroid disorders (16% in the alemtuzumab group) were, as previously shown, associated with alemtuzumab therapy [11].

Mitoxantrone

Mitoxantrone hydrochloride (Novantrone®) is an antineoplastic, immunomodulatory agent that is indicated for use in secondary progressive MS (SPMS), in progressive-relapsing MS, and for worsening relapsing-remitting MS. Mitoxantrone, a synthetic anthracyclenedione derivative, causes DNA strand-breaks and inter strand cross-links, interferes with DNA and RNA synthesis, and inhibits the enzyme topoisomerase II [12-15]. Mitoxantrone has immunosuppressive activity on T and B lymphocytes and causes apoptosis of B lymphocytes and monocytes [16,17]. One placebo-controlled, double-blind, randomized, multicenter trial evaluated mitoxantrone in progressive multiple sclerosis. The primary efficacy outcome consisted of five clinical measures; change from baseline expanded disability status scale at 24 months, change from baseline ambulation index at 24 months, number of relapses treated with corticosteroids, time to first treated relapse, and change from baseline standardized neurological status at 24 months. Primary outcomes of the trial were as followed: a change in expanded disability status scale (0.24 [0.04-0.44]; p=0.0194), change in ambulation index (0.21 [0.02-0.40]; p=0.0306), adjusted total number of treated relapses (0.38 [0.18-0.59]; p=0.0002), time to first treated relapse (0.44 [0.20-0.69]; p=0.0004), and change in standardized neurological status (0.23 [0.03-0.43]; p=0.0268). Results showed that Mitoxantrone 12 mg/m² was generally well tolerated and reduced progression of disability and clinical exacerbations against placebo, however, potential toxicity should be taken into account [18] (Table 1).

Table 1: Clinical Trials for Alemtuzumab and Natalizumab in Relapsing-Remitting Multiple Sclerosis (RRMS)

| Trial Name and Duration | Treatment Groups | Results |
|-------------------------|------------------|--------|
| Alemtuzumab CARE-MS I (n=563) [19] | Alemtuzumab 12 mg daily for 5 days at start of treatment and for 3 days at 12 months (n=376) Interferon beta-1a 44mcg three times per week (n=187) | At two years, Alemtuzumab significantly reduced the proportion of patients with any relapse (22% vs. 40% for interferon beta-1a, RR 0.45, 95% CI 0.23-0.63) and the annualized relapse rate (0.18 vs. 0.39). There was no significant difference between groups for sustained accumulation of disability (8% vs. 11%). |
| Alemtuzumab CARE-MS II (n=840) [20] | Interferon beta-1a 44mcg (n=202) Alemtuzumab 12mg/day (n=426) Alemtuzumab 24mg/day (n=170) | At two years, alemtuzumab significantly reduced the proportion of patients with any relapse (35% vs. 53% for interferon beta-1, RR 0.52, 95% CI 0.39-0.65) and the annualized relapse rate (0.26 vs. 0.52). Unlike CARE-MS I, the alemtuzumab group in CARE-MS II had a significantly lower rate of sustained accumulation of disability (13 vs. 20%, hazard ratio 0.58, 95% CI 0.38-0.87). |
| Natalizumab AFFIRM (n=942) [21] | Patients were randomly assigned to receive either Natalizumab 300mg (n=627) or placebo (n=315) every 4 weeks and have experience at least one relapse in the preceding year. | Patients receiving Natalizumab were found to have a relapse rate of 25% per patient year when compared to a relapse rate of 74% in the placebo group. |
| Natalizumab SENTINEL (n=1171) [22] | Patients were randomly assigned to receive either Natalizumab 300mg (n=589) or placebo (n=582) as well as Interferon beta-1a 10mcg. Patients had previously experienced a relapse despite previous treatment with interferon | Patients receiving Natalizumab were found to have a relapse rate of 36% per patient year compared with a relapse rate of 78% per patient year in the placebo group. |
Conclusion

Infusion therapy with the use of Alemtuzumab and Natalizumab are the mainstay of treatment for patients with RRMS. Although no head-to-head trials have directly compared these two agents, infusion therapy with Natalizumab is the drug of choice in those patients who value effectiveness above safety and convenience [19,20]. The justification for the use of these agents is based upon cross-trial comparisons and clinical experience however their superior efficacy over other disease-modifying therapies for RRMS cannot be defined confidently. We have reviewed the literature surrounding the use of these infusion therapies and have proven their efficacy through the reduction in annualized relapse rate in RRMS. Both Natalizumab and Alemtuzumab have revolutionized the treatment approach to RRMS and have lessened the clinical burden in those patients affected by this debilitating autoimmune disease [21].

References

1. Goldenberg MM (2012) Multiple sclerosis review. 37: 175-84.
2. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15: 545-558.
3. Hutchinson MN (2007) A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag 3: 259-68.
4. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, kappos I, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
5. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
6. Genzyme (2014) Lemtrada™ (alemtuzumab) injection, for intravenous use.
7. Waldmann H, Hale G (2005) CAMPATH: from concept to clinic. Phil Trans Roy Soc Lond B Biol Sci 360: 1707-1711.
8. Hu Y, Turner M, Shields J, Gale M, Hutto E, et al. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD352 transgenic mouse model. Immunology 128: 260-270.
9. Wiendl H, Kieseier B (2013) Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS. Nat. Rev. Neurou 9: 125-126.
10. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, et al. (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: A randomized controlled phase 3 trial. Lancet 380: 1819-1828.
11. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, et al. (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 380: 1829-1839.
12. Crespi MD, Ivanièr SE, Genovesi J, Baldì A (1986) Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun 136: 521-528.
13. Fidler JM, Deloy SQ, Smith FR, Gibbons JJ (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. Non-specific adherent suppressor cell derived from mitoxantrone treated mice. J Immunol 136: 2747-2754.
14. Fidler JM, Deloy SQ, Gibbons JJ (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. Suppression of B lymphocyte function. J Immunol 137: 727-732.
15. Rosenberg LS, Carvlin MJ, Krugh TR (1986) The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation. Biochemistry 25: 1002-1008.
16. Müller HLU, Tanneberger S (1987) "Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity." Anticancer Res 7: 1257-1264.
17. Bellosillo B, Colomer D, Pons G, Gil J (1998) "Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells." Br J Haematol 100: 142-146.
18. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360: 2018-2025.
19. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, et al. (2012) CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380: 1819-1828.
20. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, et al. (2012) CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380: 1829-1839.
21. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.